Ultime notizie per Certara (NASDAQ:CERT) Azioni

Certara

Certara Inc accelerates medicines to patients using biosimulation software and technology to transform traditional drug discovery and development. It provides modeling and simulation, regulatory science, and assessment software and services to help clients reduce clinical trials, accelerate regulatory approval and increase patient access to medicines. The company has its business presence in the Americas which is also it key revenue generating market, EMEA and Asia Pacific region.

Woman,Hand,Holding,Plus,Icon,For,The,Healthcare,Medical,Icon.

News

Short Ideas

Pre-Market Outlook

Markets

CERT

SMMT

THRD

L&#39;analisi tecnica evidenzia segnali potenzialmente critici per alcuni titoli della salute. L&#39;indicatore RSI invita alla massima cautela.

3 titoli del settore sanitario che sarebbe meglio scaricare questo trimestre

Certara Inc

CertiK

CERTIVE SOLUTIONS INC by Certive Solutions, Inc.

Certive Solutions Inc

Wells Fargo analyst Brandon Couillard maintains Thermo Fisher Scientific (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TMO#NYSE">TMO</a>) with a Overweight and lowers the price target from $570 to $565.

Price Target

Analyst Ratings

Wells Fargo Maintains Overweight on Thermo Fisher Scientific, Lowers Price Target to $565

Truist Securities analyst Brian Foran maintains Synchrony Financial (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SYF#NYSE">SYF</a>) with a Hold and raises the price target from $68 to $76.

Truist Securities Maintains Hold on Synchrony Financial, Raises Price Target to $76

Wells Fargo analyst Larry Biegelsen maintains Boston Scientific (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BSX#NYSE">BSX</a>) with a Overweight and raises the price target from $118 to $124.

Wells Fargo Maintains Overweight on Boston Scientific, Raises Price Target to $124

<ul>
<li>The presentation will include data from over 90 patients in both the plaque brachytherapy and enucleation-eligible cohorts</li>
<li>Darovasertib has received U.S. FDA Breakthrough Therapy Designation for use in neoadjuvant uveal melanoma for subjects requiring enucleation</li>
<li>Initiated a multi-site, global randomized Phase 3 neoadjuvant registrational trial in primary uveal melanoma (OptimUM-10) in Q3 2025</li>
</ul>
SOUTH SAN FRANCISCO, Calif., July 24, 2025 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IDYA#NASDAQ">IDYA</a>), a leading precision medicine oncology company, today announced that results from a multi-site global Phase 2 study of neoadjuvant darovasertib in primary uveal melanoma was accepted for a Proffered Paper oral presentation at the 2025 European Society of Medical Oncology (ESMO) meeting, taking place on October 17-21 in Berlin, Germany. A summary of the data from the abstract will be shared at a future date.&nbsp;

IDYA

IDEAYA Biosciences To Present Results From Multi-Site Global Phase 2 Study Of Neoadjuvant Darovasertib In Primary Uveal Melanoma At 2025 ESMO Meeting

Wells Fargo analyst Mike Mayo maintains Northern Trust (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTRS#NASDAQ">NTRS</a>) with a Equal-Weight and raises the price target from $111 to $120.

NTRS

Wells Fargo Maintains Equal-Weight on Northern Trust, Raises Price Target to $120

Truist Securities analyst Brandon King maintains Comerica (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CMA#NYSE">CMA</a>) with a Hold and raises the price target from $61 to $68.

Truist Securities Maintains Hold on Comerica, Raises Price Target to $68

Earnings

Earnings Beats

CORRECTION: Ryder System Q2 Adj. EPS $3.32 Beats $3.14 Estimate, Sales $3.19B Beat $3.18B Estimate

AVANT's Trusted Advisors Will Now Offer Enterprise-Ready Conversational AI Agents from SoundHound
SoundHound AI, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOUN#NASDAQ">SOUN</a>), a global leader in voice artificial intelligence, today announced a strategic partnership with AVANT Communications, the nation's premier Technology Services Distributor (TSD) and the leader in IT decision-making. Through this partnership, AVANT's expansive network of Trusted Advisors will be able to offer SoundHound's <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.soundhound.com%2Fvoice-ai-products%2Famelia%2F&amp;esheet=54295604&amp;newsitemid=20250724727855&amp;lan=en-US&amp;anchor=Amelia+7.0+AI+agent+platform&amp;index=1&amp;md5=3d62f099be6e0c796757b37c5341a359">Amelia 7.0 AI agent platform</a> and <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.soundhound.com%2Fvoice-ai-products%2Fautonomics%2F&amp;esheet=54295604&amp;newsitemid=20250724727855&amp;lan=en-US&amp;anchor=Autonomics+platform&amp;index=2&amp;md5=eef4c8dabc9a446da4c2d3d22a067956">Autonomics platform</a>, enabling clients to deploy leading-edge AI agents that automate customer service and business operations at scale.

SOUN

SoundHound AI Forms Strategic Alliance With AVANT Communications To Deploy Amelia 7.0 And Autonomics Platforms Across U.S. IT Network

Wells Fargo analyst Elyse Greenspan maintains Chubb (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CB#NYSE">CB</a>) with a Equal-Weight and lowers the price target from $285 to $267.

Wells Fargo Maintains Equal-Weight on Chubb, Lowers Price Target to $267

Wells Fargo analyst Timur Braziler maintains Popular (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BPOP#NASDAQ">BPOP</a>) with a Overweight and raises the price target from $135 to $140.

BPOP

Wells Fargo Maintains Overweight on Popular, Raises Price Target to $140

Truist Securities analyst David Smith maintains Ally Financial (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALLY#NYSE">ALLY</a>) with a Buy and raises the price target from $44 to $45.

ALLY

Truist Securities Maintains Buy on Ally Financial, Raises Price Target to $45

<a href="https://www.benzinga.com/money/what-is-ethereum-etf">Ethereum ETFs</a> attracted $332.18 million in net inflows on July 23, marking their fourteenth straight day of positive flows and signaling an intensifying institutional rotation from Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) into Ether (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>).
What Happened: BlackRock's (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ETHA#NASDAQ">ETHA</a>) led the charge with a $324.63 million single-day net inflow, contributing to a cumulative $8.9 billion since launch.
In contrast, Bitcoin spot ETFs posted net outflows of $85.9 million, extending a three-day streak of profit-taking.
According to <a href="https://sosovalue.com/assets/etf/us-eth-spot">data</a> from SoSoValue, Ethereum ETF net assets now stand at $19.6 billion, roughly 4.57% of the asset's market capitalization.
This includes inflows from major sponsors such as Grayscale, Fidelity, VanEck, and Bitwise. 
Meanwhile, Bitcoin ETFs, including BlackRock's (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IBIT#NASDAQ">IBIT</a>) and Fidelity's (BATS:<a class="ticker" href="https://www.benzinga.com/stock/FBTC#BATS">FBTC</a>), recorded a cumulative $54.4 billion in net inflows, but recent sessions have seen sentiment cool.
Also Read: <a href="https://www.benzinga.com/crypto/cryptocurrency/25/07/46575442/bny-taps-goldman-tech-to-tokenize-traditional-finance-blackrock-fidelity-join-in">BNY Taps Goldman Tech To Tokenize Traditional Finance—BlackRock, Fidelity Join In</a>
What Experts Are Saying: Marcin Kazmierczak, co-founder of RedStone, says this inflow streak into Ethereum reflects "growing confidence in Ethereum's utility beyond just a store of value."
He noted over $2.1 billion in weekly inflows and a record $726 million surge on July 16, framing the shift as tactical rebalancing from Bitcoin, which recently saw 20% monthly gains, to Ethereum, which rallied over 50%.
Bitfinex analysts added that Ethereum's unique yield-bearing features, particularly post-upgrade staking, are drawing attention from small-cap corporate treasuries. 
"This could redefine how such companies are valued," they noted, suggesting a shift toward ETH as a proxy asset. 
However, they warned that smaller firms may face greater risk due to volatility, regulatory uncertainty, and financial reporting challenges tied to crypto holdings.
Iliya Kalchev, analyst at Nexo Dispatch, framed the ETF flows within a broader macro and market context. 
"Bitcoin held firm above $118,000 in a choppy session, even as momentum slowed," he said. 
Despite selective pullbacks, the total crypto market cap remains elevated at $3.84 trillion. 
"Institutional flows and macro cues are playing a bigger role in shaping sentiment," Kalchev added, pointing to the upcoming Federal Reserve meeting and White House crypto policy report as key catalysts.
Ethereum dropped 4% on the day to $3,550 but maintained momentum in ETF markets. 
"ETH futures now account for 38% of aggregate open interest — their highest level since April 2023," Kalchev noted. 
He also flagged improving trade sentiment, earnings divergence in equities, and rate decisions in the U.S. and Japan as macro drivers that could impact digital asset flows in the days ahead.
With institutional appetite rising and structural adoption accelerating, Ethereum's liquidity, yield mechanics, and increasing derivatives footprint appear to be cementing its status as the next major allocation after Bitcoin.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/crypto/cryptocurrency/25/07/46574013/why-is-marathon-raising-1b-without-paying-interest-the-real-bet-behind-its-bold-bitcoin-move">Why Is Marathon Raising $1B Without Paying Interest? The Real Bet Behind Its Bold Bitcoin Move</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

$ETH

ETHA

Fidelity Wise Origin Bitcoin Fund Fidelity Wise Origin Bitcoin Fund

FBTC

IBIT

$332 Million To Minus $85 Million: Why Are Ethereum ETFs Suddenly More Popular Than Bitcoin ETFs?

Wells Fargo analyst Timur Braziler maintains BankUnited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BKU#NYSE">BKU</a>) with a Overweight and raises the price target from $42 to $45.

Wells Fargo Maintains Overweight on BankUnited, Raises Price Target to $45

Wells Fargo analyst Praneeth Satish maintains Enphase Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENPH#NASDAQ">ENPH</a>) with a Overweight and raises the price target from $42 to $45.

ENPH

Wells Fargo Maintains Overweight on Enphase Energy, Raises Price Target to $45

Heartland Express (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HTLD#NASDAQ">HTLD</a>) reported quarterly losses of $(0.14) per share which missed the analyst consensus estimate of $(0.06) by 141.38 percent. This is a 250 percent decrease over losses of $(0.04) per share from the same period last year. The company reported quarterly sales of $210.39 million which missed the analyst consensus estimate of $230.59 million by 8.76 percent. This is a 23.43 percent decrease over sales of $274.75 million the same period last year.

Earnings Misses

HTLD

Heartland Express Q2 EPS $(0.14) Misses $(0.06) Estimate, Sales $210.39M Miss $230.59M Estimate

Wells Fargo analyst Michael Blum maintains GE Vernova (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GEV#NYSE">GEV</a>) with a Overweight and raises the price target from $474 to $697.

Wells Fargo Maintains Overweight on GE Vernova, Raises Price Target to $697

<ul>
<li>TSLA</li>
<li>UNH</li>
<li>AEO</li>
<li>RKT</li>
<li>GOOGL</li>
<li>CLOV</li>
<li>FUBO</li>
<li>GOOG</li>
<li>DNUT</li>
<li>GLD</li>
</ul>
Data from <a href="https://swaggystocks.com/dashboard/wallstreetbets/ticker-sentiment">https://swaggystocks.com/dashboard/wallstreetbets/ticker-sentiment</a>
&nbsp;

Trading Ideas

CLOV

DNUT

FUBO

GOOG

GOOGL

TSLA

Top 10 Trending Stocks On WallStreetBets As Of July 24, 2025 (Via Swaggy Stocks)

Truist Securities analyst Tobey Sommer maintains Science Applications Intl (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAIC#NASDAQ">SAIC</a>) with a Hold and raises the price target from $100 to $110.

SAIC

Truist Securities Maintains Hold on Science Applications Intl, Raises Price Target to $110

VivoPower International PLC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VVPR#NASDAQ">VVPR</a>, the "Company"))), the first publicly listed company in the world with a treasury strategy to accumulate and hold XRP ("XRP"), today announced that the Nasdaq Options Market has advised that it will begin listing standardized options on VVPR, effective Friday, July 25, 2025.
The decision by NASDAQ to initiate options trading is based on an increase in perceived institutional and retail investor interest in VVPR's stock over the last few months.
Options trading on VVPR will include a range of standard expiration dates and strike prices. Trading will be cleared through the Options Clearing Corporation (OCC) and governed by the standard rules of Nasdaq and the OCC.
Options will be listed under the ticker symbol VVPR on the Nasdaq Options Market.

VVPR

Nasdaq Options Market To List VivoPower Standardized Options Effective July 25, 2025

Wells Fargo analyst Zachary Fadem maintains Chipotle Mexican Grill (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CMG#NYSE">CMG</a>) with a Overweight and lowers the price target from $65 to $60.

Comments

Certara

Notizie

Ultime notizie per Certara (NASDAQ:CERT) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO